L
Laetitia Dahan
Researcher at Aix-Marseille University
Publications - 169
Citations - 6475
Laetitia Dahan is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Gemcitabine & Bevacizumab. The author has an hindex of 34, co-authored 151 publications receiving 5377 citations. Previous affiliations of Laetitia Dahan include University of the Mediterranean & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Aaron I. Vinik,Jen-Shi Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,Dongrui Ray Lu,C. Blanckmeister,Richard C. Chao,Philippe Ruszniewski +19 more
TL;DR: Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.
Journal ArticleDOI
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
Christophe Mariette,Laetitia Dahan,F. Mornex,Emilie Maillard,Pascal-Alexandre Thomas,Bernard Meunier,Valérie Boige,Denis Pezet,William B. Robb,Valérie Le Brun-Ly,Jean-François Bosset,Jean-Yves Mabrut,Jean-Pierre Triboulet,Laurent Bedenne,Jean-François Seitz +14 more
TL;DR: Compared with surgery alone, NCRT with cisplatin plus fluorouracil does not improve R0 resection rate or survival but enhances postoperative mortality in patients with stage I or II EC.
Journal ArticleDOI
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
A. Goncalves,Marine Gilabert,E. Francois,Laetitia Dahan,Hervé Perrier,R. Lamy,D. Re,Rémy Largillier,Mohamed Gasmi,X. Tchiknavorian,Benjamin Esterni,Dominique Genre,Laurence Moureau-Zabotto,M Giovannini,J.F. Seitz,J. R. Delpero,Olivier Turrini,Olivier Turrini,Patrice Viens,J-L. Raoul +19 more
TL;DR: The addition of sorafenib to gemcitabine does not improve PFS in APC patients and the overall response rates were similar (19 and 23%, respectively).
Journal ArticleDOI
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Alix Portal,Simon Pernot,David Tougeron,Claire Arbaud,Anne Thirot Bidault,Christelle De La Fouchardiere,Pascal Hammel,Thierry Lecomte,Johann Dreanic,Romain Coriat,Jean-Baptiste Bachet,Olivier Dubreuil,Lysiane Marthey,Laetitia Dahan,Belinda Tchoundjeu,Christophe Locher,Céline Lepère,Franck Bonnetain,Julien Taieb +18 more
TL;DR: Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort is presented.
Journal ArticleDOI
Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies
Joseph Ciccolini,Laetitia Dahan,Nicolas André,Alexandre Evrard,Muriel Duluc,A. Blesius,Chenguang Yang,Sarah Giacometti,Caroline Brunet,Caroline Raynal,Adrien Ortiz,Nicolas Frances,Athanassios Iliadis,Florence Duffaud,Jean-François Seitz,Cédric Mercier +15 more
TL;DR: It is demonstrated that CDA deficiency, found in 7% of adult patients, is associated with a maximum risk of developing early severe toxicities with gemcitabine, and CDA functional testing could be a simple and easy marker to discriminate adult patients atrisk of developing severe toxicITIES with gem citabine.